← Azimuth Daily
Capturing data…
Capturing data…
FRI, 25 SEPT · 76 ITEMS
"Kyverna's cell therapy shows lasting benefit in autoimmune disease" — STAT News · Science & Medicine
Kyverna Therapeutics reported one-year data for its , (mivocabtagene autoleucel), showing durable clinical responses and a favorable safety profile in two rare autoimmune diseases: and . The results bring Kyverna closer to becoming the first company to file for FDA approval of a cell therapy for an autoimmune indication.
The claim is based on Kyverna's own press release of one-year clinical data, which is a primary source. STAT News and other outlets are reporting the company's announcement faithfully, but independent verification of the data has not yet been published. The reporting sits close to the primary source, but the solidity of the underlying clinical results depends on the full dataset and peer review.
This is genuinely new, published on September 24, 2026, based on the grounding window.